Use of multiple biomarkers in heart failure.
Biomarkers are becoming increasingly available for clinical use, particularly in the care of patients with heart failure. For health care providers, a major difficulty is how to interpret and apply these increasing amounts of diagnostic and prognostic information. Consequently, the scientific challenge is evolving from the discovery of biomarkers to the selection and validation of select panels of clinically useful markers that balance performance and practicality. Optimal combinations of biomarkers will vary based on the intended use (eg, diagnosis vs prognosis). The final goal must be to generate more actionable knowledge that improves patient management and outcomes, rather than merely creating greater complexity. Here we conceptually define multiple biomarker strategies, provide examples of emerging biomarker panels used in the care of patients with heart failure, and address key statistical and clinical issues for this rapidly evolving field.
Allen
Larry A
LA
Division of Cardiology, Colorado Cardiovascular Outcomes Research Consortium and Section of Heart Failure and Cardiac Transplantation, University of Colorado Denver, Aurora, CO 80045, USA. larry.allen@ucdenver.edu.
D015415:Biomarkers; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008403:Mass Screening; D015233:Models, Statistical; D011379:Prognosis; D018570:Risk Assessment
D015415:Biomarkers